Stock Analysis on Net

Boston Scientific Corp. (NYSE:BSX)

$22.49

This company has been moved to the archive! The financial data has not been updated since May 4, 2023.

Analysis of Income Taxes

Microsoft Excel

Paying user area

The data is hidden behind: . Unhide it.

This is a one-time payment. There is no automatic renewal.


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Income Tax Expense (Benefit)

Boston Scientific Corp., income tax expense (benefit), continuing operations

US$ in millions

Microsoft Excel
12 months ended: Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018
Federal
State
Foreign
Current
Federal
State
Foreign
Deferred
Income tax expense (benefit)

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).


Current Income Tax Expense
The current income tax expense showed a fluctuating trend over the five-year period. It began with a negative value of -87 million US dollars in 2018, indicating a tax benefit. The value increased substantially to 275 million in 2019, then slightly decreased to 87 million in 2020. From 2020 onward, the current tax expense rose consistently, reaching 178 million in 2021 and peaking at 450 million in 2022. This upward movement in recent years suggests increasing taxable income or changes in tax regulations affecting the current tax liability.
Deferred Income Tax Expense
The deferred income tax expense demonstrated considerable volatility. In 2018, the deferred tax was a negative expense (a benefit) of 162 million. It significantly increased in magnitude to -4,288 million in 2019, representing a substantial deferred tax benefit. However, in the following years, the deferred expense values moved closer to zero, with -85 million in 2020, -142 million in 2021, and a minimal -7 million in 2022. This sharp decrease in deferred tax benefit after 2019 suggests that the large deferred tax assets or liabilities recognized in that year were substantially utilized or adjusted in subsequent periods.
Total Income Tax Expense (Benefit)
The total income tax expense, which is the sum of current and deferred taxes, reflected the combined effect of the two components. It started with a total tax benefit of -249 million in 2018. In 2019, the total tax benefit dramatically increased to -4,013 million, largely driven by the extreme deferred tax benefit. From 2020 onwards, the total income tax expense shifted to a positive expense: 2 million in 2020, 36 million in 2021, and a notable increase to 443 million in 2022. This reversal from a large tax benefit in 2019 to increasing tax expenses suggests significant changes in the company's tax position, possibly driven by evolving profitability, tax planning strategies, or regulatory impacts.

Effective Income Tax Rate (EITR)

Boston Scientific Corp., effective income tax rate (EITR) reconciliation

Microsoft Excel
Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018
U.S. federal statutory income tax rate
State income taxes, net of federal benefit
Domestic taxes on foreign earnings
Effect of foreign taxes
Acquisition-related
Research credit
Valuation allowance
Goodwill impairment charges
Compensation-related
Non-deductible expenses
Uncertain tax positions
Intra-entity asset transfers
Return to provision
Change in tax rates
Other, net
Effective income tax rate, before TCJA net impact
TCJA net impact
Effective income tax rate

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).


The analysis of the annual financial tax-related data reveals significant volatility and notable shifts in the effective income tax rate and its components over the five-year period.

U.S. Federal Statutory Income Tax Rate
The federal statutory tax rate remained stable at 21% throughout the entire period, indicating no changes to the baseline federal tax obligations.
State Income Taxes, Net of Federal Benefit
There was a marked increase from a minimal 0.1% in 2018 to 6.7% in 2019, followed by a sharp decline to -16.6% in 2020. Subsequently, it returned to moderate positive levels in 2021 (2.5%) and 2022 (0.7%). This variability suggests fluctuating impacts from state tax jurisdictions and associated benefits.
Domestic Taxes on Foreign Earnings
Values exhibited extreme fluctuations: starting low at 0.5% in 2018, dramatically increasing to 21.9% in 2019, plunging to -155.4% in 2020, then recovering to positive contributions in 2021 (6.8%) and 2022 (15.3%). This pattern implies significant adjustments related to international earnings and associated tax treatments.
Effect of Foreign Taxes
The influence of foreign taxes was consistently negative but showed a fluctuating trend, decreasing from -8.4% in 2018 to -47.6% in 2019, then turning positive at 40.7% in 2020, followed by a return to negative values in 2021 (-14.3%) and 2022 (-3.8%). Such oscillations indicate variable foreign tax credit effects or foreign jurisdiction tax rate impacts on overall taxation.
Acquisition-Related Tax Effects
Starting at 2.1% in 2018, acquisition-related impacts peaked at 16.7% in 2020 before dropping to -8.1% in 2021, and recovering slightly to 4.4% in 2022. This suggests intensified acquisition activity affecting tax liabilities, with periods of both tax expense increases and decreases.
Research Credit
The research credits fluctuated, with negative contributions in most years except 2020, where a substantial positive 43% impact was observed. This spike could reflect credit recognition timing or significant qualifying expenditures in that year.
Valuation Allowance
The valuation allowance showed negative effects in 2018 (-5.2%) and 2022 (-1.3%), a small positive effect in 2019 (1.1%), and a notable 42% positive effect in 2020, with a negligible positive effect in 2021 (0.8%). The large positive shift in 2020 may indicate reversal or recognition of deferred tax assets.
Goodwill Impairment Charges
Goodwill impairment was recorded only in 2020 at -3.7%, reflecting a non-recurring charge impacting tax calculations in that year.
Compensation-Related Tax Effects
These effects remained near neutral or slightly negative except a notable increase to 7.7% in 2020, suggesting changes in deductible compensation expenses affecting tax obligations.
Non-Deductible Expenses
There was a significant negative spike in 2020 (-64.4%), contrasting with small positive impacts in other years, indicating unusual adjustments or non-deductible expenses primarily impacting that year.
Uncertain Tax Positions
This item showed wide variability from a significant negative effect (-22%) in 2018 to a sharp rise to 96.8% in 2020, followed by lower but positive contributions in 2021 (1.2%) and 2022 (7.7%). Such changes suggest evolving assessments of tax uncertainties and related reserves.
Intra-Entity Asset Transfers
Notable large negative effect of -597% in 2019 and -10.2% in 2020 with no recorded impacts in other years, indicative of substantial intercompany asset transfer adjustments influencing tax computations.
Return to Provision
Minor negative effects in most years aside from a significant positive 37.3% in 2020, showing occasional releases or additions to tax provisions.
Change in Tax Rates
This factor remained generally small, with a large negative effect (-51.8%) in 2020 and marginal fluctuations in other years, pointing to limited statutory tax rate changes or re-measurements during the period.
Other, Net
Other net impacts varied modestly across the years, with no pronounced trends.
Effective Income Tax Rate Before TCJA Net Impact
This metric exhibited extreme variance, plunging to -584% in 2019 and displaying a negative rate in 2018 (-12.8%) and 2020 (-2.9%), moving to positive in 2021 (3.3%) and surging to 38.9% in 2022. These swings reflect the cumulative effect of the aforementioned volatile components.
TCJA Net Impact
Reported only in 2018 as -4.7%, reflecting the residual tax impact of the Tax Cuts and Jobs Act for that reporting year.
Effective Income Tax Rate
Mirroring the rate before TCJA impact, the overall effective income tax rate demonstrated high volatility with negative effective rates in 2018, 2019, and 2020, followed by modest positive taxation in 2021, and a sharp increase to 38.9% in 2022, indicative of significantly higher tax burdens in the most recent year.

In summary, the tax-related financial metrics are characterized by considerable volatility, especially during the 2019–2020 period, driven by substantial one-time events such as intra-entity asset transfers, uncertain tax position adjustments, and the impact of foreign earnings. The effective income tax rates fluctuate markedly, with negative rates indicating net tax benefits or deferred tax asset recognition in certain years, particularly 2019 and 2020, and a notable increase in tax expense recognized by 2022. This pattern suggests dynamic tax strategies and varying operational factors affecting taxable income and tax liabilities over the examined period.


Components of Deferred Tax Assets and Liabilities

Boston Scientific Corp., components of deferred tax assets and liabilities

US$ in millions

Microsoft Excel
Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018
Inventory costs and related reserves
Tax benefit of net operating loss and credits
Reserves and accruals
Restructuring-related charges
Litigation and product liability reserves
Investment write-down
Compensation related
Federal benefit of uncertain tax positions
Intangible assets
Capitalized R&D
Property, plant and equipment
Other
Deferred tax assets
Valuation allowance
Deferred tax assets, less valuation allowance
Property, plant and equipment
Unrealized gains and losses on derivative financial instruments
Investment write-up
Intangible assets
Inventory costs and related services
Other
Deferred tax liabilities
Net deferred tax assets (liabilities)

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).


Inventory Costs and Related Reserves
The inventory costs and related reserves display variability over the analyzed periods, dropping from 18 million in 2018 to 10 million in both 2020 and 2021, then rising sharply to 19 million in 2022. This fluctuation suggests episodic adjustments impacting inventory valuation or related provisions.
Tax Benefit of Net Operating Loss and Credits
This item shows a general upward trend from 450 million in 2018 to a peak of 620 million in 2021, followed by a decline to 511 million in 2022. The increase up to 2021 indicates growing utilization or recognition of tax benefits, whereas the decline in 2022 may reflect changes in tax positions or operating losses.
Reserves and Accruals
Reserves and accruals moderately increased from 258 million in 2018 and 2019 to 308 million in 2020, peaking at 324 million in 2021, then slightly decreasing to 304 million in 2022. This steady upward movement suggests growing obligations or anticipation of future expenses over the years.
Restructuring-Related Charges
Restructuring-related charges increased from 12 million in 2018 to a high of 23 million in 2020, before decreasing to 6 million by 2022. The pattern indicates significant restructuring activities concentrated around 2019-2020, with reduction in such charges in subsequent years.
Litigation and Product Liability Reserves
These reserves decreased notably from 221 million in 2018 to 82 million in 2020, rose again to 127 million in 2021, then declined to 103 million in 2022. Such fluctuations imply episodic adjustments possibly due to settlements or reassessments of legal risks.
Investment Write-downs
Investment write-downs display irregular values: starting at 28 million in 2018, increasing to 42 million in 2019, absent data for 2020, then reported as 31 million in 2021 and 38 million in 2022. This suggests recurring impairment charges affecting investments periodically.
Compensation Related Expenses
Compensation-related expenses show a consistent gradual increase from 106 million in 2018 to 136 million in 2022, signifying incremental increases in personnel costs or benefits over the years.
Federal Benefit of Uncertain Tax Positions
This item slightly decreases from 10 million in 2018 and 2019 to 8 million in 2021, before a minor increase to 9 million in 2022, pointing to relatively stable but slightly declining benefits from uncertain tax positions.
Intangible Assets
Intangible assets grow steadily from 3,447 million in 2019 to 3,666 million in 2022. This indicates ongoing investments or acquisitions in intangible resources. Negative values noted in earlier years may correspond to write-offs or adjustments.
Capitalized Research and Development
Capitalized R&D expenditures emerge during the analyzed period, escalating from 4 million in 2020 to 160 million by 2022. This suggests an increasing capitalization of development costs, reflecting strategic investments in innovation.
Property, Plant, and Equipment
Reported values are limited but indicate a significant presence of fixed assets by 2021, although the amount declines considerably by 2022. Negative values in earlier years suggest disposals or impairments prior to the inclusion of positive balances.
Other Items
The "Other" category exhibits volatility, ranging from positive values in 2018 and 2021 to negative values in 2020 and 2022, which may reflect miscellaneous gains or expenses impacting the financials inconsistently.
Deferred Tax Assets and Related Allowances
Deferred tax assets increase substantially from 1,140 million in 2018 to nearly 4,954 million in 2022. Valuation allowances also grow negatively over time, peaking at -1,014 million in 2021 and slightly improving thereafter. Net deferred tax assets (assets less valuation allowance) demonstrate a strong upward trend, rising from 796 million in 2018 to 3,950 million in 2022, indicating improved tax asset recognition after allowances.
Unrealized Gains and Losses on Derivative Financial Instruments
Unrealized losses deepen progressively from -44 million in 2018 to -117 million in 2022. This trend signals increasing unfavorable movements in derivatives or increased exposure.
Investment Write-up
The data shows a singular negative entry of -34 million in 2020, with no other values recorded, suggesting a one-time downward adjustment on investments in that year.
Deferred Tax Liabilities
Deferred tax liabilities display fluctuations, sharply decreasing from -1,037 million in 2018 to -95 million in 2019, then varying mildly before dropping again to -151 million in 2022. These movements may be related to changes in deferred tax positions corresponding to operational or fiscal shifts.
Net Deferred Tax Assets (Liabilities)
The net deferred tax position evolves from a negative balance of -241 million in 2018 to positive values between 3,601 million and 3,833 million in the subsequent years, then slightly decreasing to 3,799 million in 2022. This indicates a significant improvement in deferred tax asset positions over the period.

Deferred Tax Assets and Liabilities, Classification

Boston Scientific Corp., deferred tax assets and liabilities, classification

US$ in millions

Microsoft Excel
Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018
Deferred tax assets
Deferred tax liabilities

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).


The financial data over the period from 2018 to 2022 reveals significant changes in both deferred tax assets and deferred tax liabilities.

Deferred Tax Assets
There is a pronounced increase in deferred tax assets from 2018 to 2019, where the value surged from 87 million USD to 4,196 million USD. Following this sharp rise, the deferred tax assets remained relatively stable, fluctuating marginally around the 4,100 million USD to 4,200 million USD range over the subsequent years. By 2022, the deferred tax assets slightly declined to 3,942 million USD, indicating a minor reduction from the peak but still maintaining a significantly elevated level compared to 2018.
Deferred Tax Liabilities
The deferred tax liabilities showed a moderate increase from 328 million USD in 2018 to 595 million USD in 2019, followed by a notable decline in the subsequent years. This downward trend continued steadily, with liabilities decreasing to 330 million USD in 2020, 310 million USD in 2021, and significantly dropping to 144 million USD by 2022. This pattern suggests a consistent reduction in tax liabilities, particularly after the peak reached in 2019.

The contrasting trends between assets and liabilities indicate an overall strengthening of deferred tax asset positions accompanied by a diminishing deferred tax liability. The substantial increase in deferred tax assets in 2019 could be attributed to accounting adjustments or changes in tax planning strategies, while the subsequent stabilization suggests maintenance of these gains. The continuous decrease in liabilities points toward improved tax efficiency or reductions in taxable temporary differences.


Adjustments to Financial Statements: Removal of Deferred Taxes

Boston Scientific Corp., adjustments to financial statements

US$ in millions

Microsoft Excel
Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018
Adjustment to Total Assets
Total assets (as reported)
Less: Noncurrent deferred tax assets, net
Total assets (adjusted)
Adjustment to Total Liabilities
Total liabilities (as reported)
Less: Noncurrent deferred tax liabilities, net
Total liabilities (adjusted)
Adjustment to Stockholders’ Equity
Stockholders’ equity (as reported)
Less: Net deferred tax assets (liabilities)
Stockholders’ equity (adjusted)
Adjustment to Net Income (loss)
Net income (loss) (as reported)
Add: Deferred income tax expense (benefit)
Net income (loss) (adjusted)

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).


The financial data reveals several notable trends and adjustments between reported and adjusted figures over the five-year period ending December 31, 2022.

Total Assets
Reported total assets exhibit a consistent upward trajectory from 20,999 million USD in 2018 to 32,469 million USD in 2022. Adjusted total assets also increase but at a slower rate, moving from 20,912 million USD in 2018 to 28,527 million USD in 2022. The difference between reported and adjusted assets widens over time, suggesting that the adjustments reduce asset valuations by a growing margin, potentially reflecting deferred tax impacts or other non-cash adjustments.
Total Liabilities
Reported total liabilities show an initial increase from 12,273 million USD in 2018 to a peak of 16,688 million USD in 2019, then a general decline to 14,896 million USD by 2022. Adjusted liabilities follow a similar pattern but are consistently lower than reported figures, moving from 11,945 million USD to 14,752 million USD over the same period. The narrowing gap between reported and adjusted liabilities towards 2022 could indicate revision or reclassification of certain liabilities, possibly related to tax adjustments.
Stockholders’ Equity
Reported stockholders’ equity climbs steadily from 8,726 million USD in 2018 to 17,573 million USD in 2022, reflecting sustained equity growth. Adjusted stockholders’ equity increases from 8,967 million USD to 13,774 million USD in this timeframe, also growing but at a slower pace compared to reported equity. The persistent higher value in reported equity versus adjusted equity implies that adjustments—likely for deferred taxes—reduce reported equity levels in the adjusted figures.
Net Income (Loss)
Reported net income shows significant volatility. It rises sharply from 1,671 million USD in 2018 to a high of 4,700 million USD in 2019, followed by a loss of 82 million USD in 2020. Subsequently, income recovers to 1,041 million USD in 2021 but decreases again to 698 million USD in 2022. Adjusted net income follows a more moderated and consistently lower pattern, starting at 1,509 million USD in 2018, dipping to 412 million USD in 2019, experiencing a deeper loss of 167 million USD in 2020, and then recovering to 899 and 691 million USD in 2021 and 2022, respectively. This pattern suggests that adjustments have a dampening effect on profitability, likely reflecting the impact of deferred taxes or other income tax-related adjustments.

Overall, the data demonstrates growth in assets and equity over the period, with adjustments consistently moderating reported figures. Liabilities peak around 2019 before trending downward. Net income is notably volatile, with adjustments smoothing extremes but generally lowering reported profitability. These trends highlight the material impact of income tax adjustments on financial position and performance metrics.


Boston Scientific Corp., Financial Data: Reported vs. Adjusted


Adjusted Financial Ratios: Removal of Deferred Taxes (Summary)

Boston Scientific Corp., adjusted financial ratios

Microsoft Excel
Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018
Net Profit Margin
Reported net profit margin
Adjusted net profit margin
Total Asset Turnover
Reported total asset turnover
Adjusted total asset turnover
Financial Leverage
Reported financial leverage
Adjusted financial leverage
Return on Equity (ROE)
Reported ROE
Adjusted ROE
Return on Assets (ROA)
Reported ROA
Adjusted ROA

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).


The analysis of the financial data over the five-year period reveals distinct trends and fluctuations across profitability, asset efficiency, financial leverage, and returns metrics.

Net Profit Margin
The reported net profit margin experienced significant volatility, peaking at 43.78% in 2019 before declining sharply to a negative margin of -0.83% in 2020. It partially recovered in 2021 and 2022, reaching 8.76% and then declining slightly to 5.5%. The adjusted net profit margin follows a similar pattern but displays more conservative values, with a high of 15.36% in 2018, a notable drop to 3.84% in 2019, turning negative at -1.68% in 2020, and recovering to 7.56% and 5.45% in the subsequent years respectively.
Total Asset Turnover
The reported total asset turnover ratio showed a general declining trend from 0.47 in 2018 down to 0.32 in 2020, with a slight recovery thereafter to 0.39 by 2022. In contrast, the adjusted total asset turnover maintained a more stable and improving trajectory, decreasing from 0.47 in 2018 to 0.37 in 2020 but increasing steadily to 0.44 in 2022. This suggests an improving efficiency in asset utilization when adjusting for income tax effects and other items.
Financial Leverage
The reported financial leverage steadily decreased from 2.41 in 2018 to 1.85 in 2022, indicating a gradual reduction in reliance on debt or liabilities relative to equity. Conversely, the adjusted financial leverage appears more variable, rising to 2.57 in 2019, then declining each year to 2.07 in 2022. This indicates some adjustments that reflect variations in leverage when excluding certain income tax and deferred effects.
Return on Equity (ROE)
Reported ROE demonstrated a strong peak in 2019 (33.87%) followed by a steep fall to negative territory in 2020 (-0.54%). It then recovered marginally to 6.26% in 2021 but declined again to 3.97% in 2022. The adjusted ROE mirrors this trend but remains lower in magnitude, reaching only 4.01% at its peak in 2019, dropping to -1.44% in 2020, and improving to 7.03% and 5.02% in 2021 and 2022. This pattern reflects volatility in net income relative to shareholder equity, impacted by the reported and adjusted tax considerations.
Return on Assets (ROA)
Reported ROA follows a similar pattern to ROE and net margin with a peak in 2019 at 15.38%, followed by a negative dip in 2020 (-0.27%), and then moderate recovery towards 2.15% in 2022. Adjusted ROA maintains a less pronounced peak at 7.22% in 2018, drops significantly to 1.56% in 2019, becomes negative in 2020 (-0.63%), and recovers slightly to 2.42% in 2022. This suggests varying asset profitability that is influenced by the adjustments related to tax and other deferred items.

Overall, the data indicate a period of considerable financial performance volatility around 2019 and 2020, with substantial declines in profitability metrics followed by gradual recovery in the following years. Adjusted figures tend to moderate the extremes observed in the reported data, highlighting the importance of considering tax and deferred income adjustments when evaluating performance. Efficiency ratios show a modest improvement post-2020, while leverage levels generally decreased, suggesting a cautious approach to financial risk in recent periods.


Boston Scientific Corp., Financial Ratios: Reported vs. Adjusted


Adjusted Net Profit Margin

Microsoft Excel
Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018
As Reported
Selected Financial Data (US$ in millions)
Net income (loss)
Net sales
Profitability Ratio
Net profit margin1
Adjusted for Deferred Taxes
Selected Financial Data (US$ in millions)
Adjusted net income (loss)
Net sales
Profitability Ratio
Adjusted net profit margin2

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).

2022 Calculations

1 Net profit margin = 100 × Net income (loss) ÷ Net sales
= 100 × ÷ =

2 Adjusted net profit margin = 100 × Adjusted net income (loss) ÷ Net sales
= 100 × ÷ =


Reported Net Income (Loss)
The reported net income experienced significant fluctuation over the five-year period. It increased substantially from $1,671 million in 2018 to a peak of $4,700 million in 2019. Subsequently, there was a sharp decline resulting in a loss of $82 million in 2020. The income recovered to positive territory in 2021 with $1,041 million but decreased again to $698 million in 2022. This indicates a volatile profit performance with a notable peak followed by a loss and partial recovery.
Adjusted Net Income (Loss)
The adjusted net income exhibited a downward trend from $1,509 million in 2018 to $412 million in 2019. It then dropped further to a loss of $167 million in 2020, showing a deeper negative impact after adjusting for income tax effects. However, it rebounded to $899 million in 2021, before slightly declining to $691 million in 2022. Adjusted figures generally followed the trend of reported results but suggest more pronounced volatility and a sharper impact in 2020.
Reported Net Profit Margin
The reported net profit margin showed a strong increase from 17.01% in 2018 to 43.78% in 2019, indicating improved profitability relative to revenues. This was followed by a steep decline to negative 0.83% in 2020, indicating a loss margin. Margins recovered to 8.76% in 2021 but decreased again to 5.5% in 2022, reflecting fluctuations in profitability with an overall decline from the 2019 peak.
Adjusted Net Profit Margin
The adjusted net profit margin pattern was generally similar but lower in magnitude compared to the reported margin. It declined sharply from 15.36% in 2018 to 3.84% in 2019 and further dropped to negative 1.68% in 2020. Recovery was seen in 2021 with a margin of 7.56%, followed by a slight decrease to 5.45% in 2022. This pattern reflects the impact of tax and other adjustments on profitability, showing more conservative profit ratios especially during down years.
Summary of Trends and Insights
Overall, the financial data reveals pronounced volatility in profitability over the analyzed period. Both reported and adjusted net incomes and margins peaked in 2019, declined sharply to losses in 2020, and partially recovered in subsequent years. Adjusted results indicate that tax and deferred income considerations accentuate these fluctuations. The decline from the 2019 peak and the losses in 2020 may point to significant operational or market challenges during that time frame, with a gradual return to profitability that remains below prior peak levels. The net profit margins show that profitability relative to revenues also followed this cycle of expansion, contraction, and recovery, signaling a potentially unstable earnings environment influenced by factors affecting tax adjustments and reported results.

Adjusted Total Asset Turnover

Microsoft Excel
Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018
As Reported
Selected Financial Data (US$ in millions)
Net sales
Total assets
Activity Ratio
Total asset turnover1
Adjusted for Deferred Taxes
Selected Financial Data (US$ in millions)
Net sales
Adjusted total assets
Activity Ratio
Adjusted total asset turnover2

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).

2022 Calculations

1 Total asset turnover = Net sales ÷ Total assets
= ÷ =

2 Adjusted total asset turnover = Net sales ÷ Adjusted total assets
= ÷ =


Reported Total Assets
The reported total assets exhibited a notable increase from 20,999 million US dollars in 2018 to 32,469 million US dollars in 2022. This represents a substantial growth trend over the five-year period, with especially significant growth occurring between 2018 and 2019. Following 2019, the asset base continued to increase but at a more moderate pace.
Adjusted Total Assets
The adjusted total assets also increased, but at a slower rate compared to reported total assets. Beginning at 20,912 million US dollars in 2018, they rose to 28,527 million US dollars in 2022. The gap between reported and adjusted total assets widened over the years, indicating increasing adjustments affecting the asset base.
Reported Total Asset Turnover
The reported total asset turnover ratio showed a declining trend from 0.47 in 2018 to a low of 0.32 in 2020. However, from 2020 onwards, it reflected a recovery, increasing to 0.39 by 2022. This pattern suggests an initial decrease in asset efficiency followed by gradual improvement.
Adjusted Total Asset Turnover
The adjusted total asset turnover ratio demonstrated a somewhat different pattern. It decreased from 0.47 in 2018 to 0.37 in 2020 but maintained higher values than the reported turnover in subsequent years, reaching 0.44 in 2022. This indicates a stronger recovery and better asset utilization after adjustments compared to the unadjusted figures.
Overall Insights
Over the analyzed period, both total assets and adjusted total assets increased significantly, reflecting asset growth. The total asset turnover ratios initially decreased, reflecting reduced efficiency in asset utilization, but recovered in later years, more prominently so in adjusted figures. The divergence between reported and adjusted asset values and turnover suggests that adjustments have a meaningful impact on asset measurement and efficiency assessment.

Adjusted Financial Leverage

Microsoft Excel
Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018
As Reported
Selected Financial Data (US$ in millions)
Total assets
Stockholders’ equity
Solvency Ratio
Financial leverage1
Adjusted for Deferred Taxes
Selected Financial Data (US$ in millions)
Adjusted total assets
Adjusted stockholders’ equity
Solvency Ratio
Adjusted financial leverage2

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).

2022 Calculations

1 Financial leverage = Total assets ÷ Stockholders’ equity
= ÷ =

2 Adjusted financial leverage = Adjusted total assets ÷ Adjusted stockholders’ equity
= ÷ =


The financial data reveals distinct trends in both reported and adjusted figures over the five-year period from 2018 to 2022.

Total Assets
The reported total assets show a continuous increase each year, rising from 20,999 million USD in 2018 to 32,469 million USD in 2022. The adjusted total assets also follow an upward trend, albeit with lower absolute values compared to the reported figures, increasing from 20,912 million USD in 2018 to 28,527 million USD in 2022. The gap between reported and adjusted total assets widens over time, reflecting the effects of tax-related adjustments.
Stockholders’ Equity
Reported stockholders’ equity consistently grows from 8,726 million USD in 2018 to 17,573 million USD in 2022, nearly doubling over the period. Adjusted stockholders’ equity also shows steady growth but at lower levels, rising from 8,967 million USD in 2018 to 13,774 million USD in 2022. Notably, the adjusted equity starts slightly higher than the reported figure in 2018 but remains consistently below reported equity in subsequent years.
Financial Leverage Ratios
Reported financial leverage decreases steadily from 2.41 in 2018 to 1.85 in 2022, indicating a reduction in leverage and potentially a stronger equity base relative to liabilities. In contrast, the adjusted financial leverage exhibits more variability: it increases from 2.33 in 2018 to 2.57 in 2019, followed by a general decline to 2.07 in 2022. Although both measures trend downward in the later years, the adjusted leverage remains consistently higher than the reported leverage after 2018, suggesting that income tax adjustments affect the leverage calculations and possibly reflect higher relative debt levels when considering deferred tax impacts.

Overall, the data indicates steady growth in both assets and equity, with adjustments for deferred income tax leading to noticeable differences in asset and equity valuations as well as leverage measures. The decrease in financial leverage ratios over time, particularly in the reported figures, points to an improving capital structure with reduced reliance on debt financing. However, the higher adjusted leverage ratios suggest that tax effects may obscure some of this deleveraging when considering adjusted financial conditions.


Adjusted Return on Equity (ROE)

Microsoft Excel
Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018
As Reported
Selected Financial Data (US$ in millions)
Net income (loss)
Stockholders’ equity
Profitability Ratio
ROE1
Adjusted for Deferred Taxes
Selected Financial Data (US$ in millions)
Adjusted net income (loss)
Adjusted stockholders’ equity
Profitability Ratio
Adjusted ROE2

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).

2022 Calculations

1 ROE = 100 × Net income (loss) ÷ Stockholders’ equity
= 100 × ÷ =

2 Adjusted ROE = 100 × Adjusted net income (loss) ÷ Adjusted stockholders’ equity
= 100 × ÷ =


The data reveals distinct trends in the financial performance and position over the five-year period from 2018 to 2022. Both reported and adjusted net income display significant variability, impacting profitability metrics such as return on equity (ROE).

Net Income (Loss)
Reported net income peaked in 2019 at $4,700 million, followed by a steep decline to a loss of $82 million in 2020. Recovery efforts are noted in subsequent years with reported net income reaching $1,041 million in 2021 and then declining again to $698 million in 2022. Adjusted net income exhibits a similar trend but at generally lower levels, highlighting a loss in 2020 and progressive improvement through 2021 and 2022, albeit remaining below the 2018 figure.
Stockholders’ Equity
Both reported and adjusted stockholders’ equity show consistent growth throughout the period. Reported equity increases steadily from $8,726 million in 2018 to $17,573 million in 2022. Adjusted equity, while lower than reported figures each year, follows a similar upward trajectory, rising from $8,967 million in 2018 to $13,774 million in 2022. This indicates a strengthening equity base despite fluctuations in earnings.
Return on Equity (ROE)
Reported ROE demonstrates high volatility, with a peak of 33.87% in 2019 followed by a negative value of -0.54% in 2020. Thereafter, a moderate recovery is observed with ROE at 6.26% in 2021 and a decrease to 3.97% in 2022. Adjusted ROE mirrors this pattern but with lower magnitudes; it remains modestly positive except for the negative return in 2020 and peaks at 7.03% in 2021 before declining slightly in 2022.

Overall, the period reflects pronounced fluctuations in profitability with a sharp decline around 2020, followed by partial recovery. Meanwhile, the equity base demonstrates steady expansion, which may support future profitability improvements. The divergence between reported and adjusted figures suggests the presence of non-recurring or unusual items influencing earnings and equity metrics.


Adjusted Return on Assets (ROA)

Microsoft Excel
Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018
As Reported
Selected Financial Data (US$ in millions)
Net income (loss)
Total assets
Profitability Ratio
ROA1
Adjusted for Deferred Taxes
Selected Financial Data (US$ in millions)
Adjusted net income (loss)
Adjusted total assets
Profitability Ratio
Adjusted ROA2

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).

2022 Calculations

1 ROA = 100 × Net income (loss) ÷ Total assets
= 100 × ÷ =

2 Adjusted ROA = 100 × Adjusted net income (loss) ÷ Adjusted total assets
= 100 × ÷ =


Net Income Trends
The reported net income demonstrated significant volatility over the examined periods, initially increasing sharply from $1,671 million in 2018 to $4,700 million in 2019, followed by a substantial decline to a loss of $82 million in 2020. Subsequently, the net income recovered to $1,041 million in 2021 before decreasing again to $698 million in 2022. The adjusted net income followed a similar pattern but remained consistently lower than the reported figures, indicating that certain adjustments had a material effect on profitability. The adjusted net income showed a decrease from $1,509 million in 2018 to $412 million in 2019, further dropping to a loss of $167 million in 2020, then improving in 2021 and slightly declining in 2022.
Total Assets Trends
Total assets, both reported and adjusted, exhibited steady growth throughout the period under review. Reported total assets increased from approximately $21 billion in 2018 to around $32.5 billion in 2022. Adjusted total assets also followed an upward trajectory, rising from about $20.9 billion in 2018 to $28.5 billion in 2022. The difference between reported and adjusted asset values suggests revisions or reclassifications in asset reporting, with reported assets consistently higher than adjusted assets.
Return on Assets (ROA) Analysis
The reported ROA displayed considerable fluctuation, peaking at 15.38% in 2019 before turning negative at -0.27% in 2020. It then recovered moderately to 3.23% in 2021 but declined subsequently to 2.15% in 2022. The adjusted ROA mirrored these movements with generally lower values, peaking at 7.22% in 2018, dipping sharply to 1.56% in 2019, turning negative at -0.63% in 2020, and rebounding somewhat in the final two periods, ending at 2.42% in 2022. The discrepancies between reported and adjusted ROA figures indicate that certain non-operating or non-recurring factors impacted profitability measurements over these years.
Overall Observations
The data reveals a pattern of financial instability primarily in 2020, where the company experienced losses and negative returns on assets. This was preceded by a peak financial performance in 2019, suggesting a possible one-off gain or exceptional event during that year. Asset growth was consistent, implying ongoing investment or acquisition activity despite the fluctuations in net income and profitability. Adjustments to net income and assets suggest the presence of accounting or tax impacts that materially influence the interpretation of the company’s financial health. The partial recovery in profitability and ROA after 2020 indicates some improvement, though the levels remain below the pre-2019 peak performance.